Beyond Air, Inc. Secures U.S. Patent for Novel Nitric Oxide Delivery Method in Treating NTM Lung Infections

Beyond Air announces U.S. Patent No. 12,274,830 for delivering nitric oxide in treating NTM lung infections, enhancing its intellectual property portfolio.

Quiver AI Summary

Beyond Air, Inc. announced the issuance of U.S. Patent No. 12,274,830 by the USPTO, which protects its method for delivering gaseous nitric oxide (gNO) to treat patients with non-tuberculous mycobacteria (NTM) lung infections. This patent strengthens the company's intellectual property portfolio and highlights the potential of its LungFit program, which allows patients to self-administer nitric oxide at home. The novel dosing regimen outlined in the patent could provide significant health benefits for managing NTM infections, which are serious and treatment-resistant lung conditions. Beyond Air is also advancing multiple LungFit systems aimed at treating various lung diseases and has made strides in clinical trials for conditions like viral pneumonia and NTM. The company emphasizes the advantages of its technology over traditional nitric oxide delivery methods, aiming to improve patient outcomes and treatment accessibility.

Potential Positives

• The issuance of U.S. Patent No. 12,274,830 provides Beyond Air with exclusive protection for its novel method of delivering gaseous nitric oxide for treating NTM lung infections, strengthening its intellectual property portfolio.
• The patent supports the potential for the LungFit program, which has shown promising clinical data in the treatment of NTM lung infections, enhancing the company's market position.
• The LungFit® system offers significant advantages, such as eliminating the need for high-pressure cylinders, which could lead to improved operational efficiency and safety in clinical settings.
• The press release highlights Beyond Air's commitment to advancing treatment options for serious respiratory illnesses, aligning with growing public health concerns regarding antibiotic resistance in NTM infections.

Potential Negatives

• Though the issuance of a patent may seem positive, the press release highlights that NTM infections are rare and come with high morbidity and mortality, which could limit the market and potential revenue for Beyond Air’s treatment.
• The forward-looking statements contain significant disclaimers about the inherent risks and uncertainties associated with their product development, which could lead to skepticism regarding the company’s future performance and prospects.
• The mention of the lengthy and complex current treatment regimens for NTM infections raises questions about how effectively Beyond Air's treatment could compete in a challenging and established market of antibiotics.

FAQ

What recent patent has Beyond Air been granted?

Beyond Air has been granted U.S. Patent No. 12,274,830 for delivering gaseous nitric oxide to treat NTM lung infections.

What is the LungFit program?

The LungFit program aims to provide safe and effective treatment for NTM lung infections using self-administered nitric oxide at home.

How does nitric oxide help with lung infections?

Nitric oxide targets vascular smooth muscle in the lungs and possesses anti-microbial activity against various pathogens, including mycobacteria.

What is NTM lung infection?

NTM lung infection is a rare, serious bacterial infection acquired from the environment, leading to progressive lung disease.

Where can I find more information about Beyond Air?

More information about Beyond Air and its products can be found on their official website at www.beyondair.net.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$XAIR Insider Trading Activity

$XAIR insiders have traded $XAIR stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $XAIR stock by insiders over the last 6 months:

• ROBERT CAREY has made 2 purchases buying 1,000,000 shares for an estimated $250,050 and 0 sales.
• MICHAEL A. GAUL (Chief Operating Officer) purchased 6,000 shares for an estimated $2,293

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$XAIR Hedge Fund Activity

We have seen 18 institutional investors add shares of $XAIR stock to their portfolio, and 24 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• ALYESKA INVESTMENT GROUP, L.P. added 7,142,199 shares (+inf%) to their portfolio in Q4 2024, for an estimated $2,560,478
• BALYASNY ASSET MANAGEMENT L.P. added 3,334,409 shares (+inf%) to their portfolio in Q4 2024, for an estimated $1,195,385
• AIGH CAPITAL MANAGEMENT LLC removed 2,611,515 shares (-72.5%) from their portfolio in Q4 2024, for an estimated $936,228
• LASRY MARC removed 2,154,365 shares (-43.6%) from their portfolio in Q4 2024, for an estimated $772,339
• SOROS FUND MANAGEMENT LLC removed 476,626 shares (-32.3%) from their portfolio in Q4 2024, for an estimated $170,870
• ADAR1 CAPITAL MANAGEMENT, LLC removed 282,131 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $101,143
• GEODE CAPITAL MANAGEMENT, LLC added 251,823 shares (+81.0%) to their portfolio in Q4 2024, for an estimated $90,278

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$XAIR Analyst Ratings

Wall Street analysts have issued reports on $XAIR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

• Piper Sandler issued a "Overweight" rating on 11/12/2024

To track analyst ratings and price targets for $XAIR, check out Quiver Quantitative's $XAIR forecast page.

Full Release

GARDEN CITY, N.Y., April 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,274,830. The issued patent gives the Company protection for its method of delivering gaseous nitric oxide (gNO) to a patient that has a condition associated with non-tuberculous mycobacteria (NTM) lung infection.

“This latest patent further strengthens our growing intellectual property portfolio and reinforces the potential of our LungFit program,” said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. “We recently announced the publication of positive clinical data in the American Thoracic Society Journal showing the potential LungFit GO has in safe and effective treatment of NTM lung infections with patients self-administering NO at home.”

The allowed claims in this patent encompass a novel dosing regimen of 200 ppm to 320 ppm gNO for 10 to 45 minutes, 2 to 5 times per day, to provide a nitric oxide-load (NO load) of 300 ppm-hrs to 900 ppm-hrs of gNO per day over a period of at least 14 days. The patent will expire on March 12, 2038.

NTM infection is a rare and serious bacterial infection in the lungs causing debilitating pulmonary disease associated with high morbidity and mortality. NTM infection is acquired by inhaling aerosolized bacteria from the environment, and can lead to NTM lung disease, a progressive and chronic condition. According to the Cystic Fibrosis Foundation, 13% of U.S. cystic fibrosis patients had a positive culture for a NTM species in 2017. NTM is an emerging public health concern worldwide because of its multi-drug antibiotic resistance. Current treatment guidelines suggest a combination of multiple antibiotics dosed chronically for as long as two years. These complex, expensive and invasive regimens have a poor record in the treatment of Mycobacterium abscessus complex (MABSC) and refractory Mycobacterium avium complex (MAC) and may cause severe adverse events.

About Beyond Air®, Inc.

Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit® systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).

The Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit

www.beyondair.net

.

About LungFit®*

Beyond Air’s LungFit® is a cylinder-free, phasic flow generator and delivery system designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator-compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit® system could potentially replace large, high-pressure NO cylinders, providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety by eliminating NO2 purging steps, and offering other operational benefits.

LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g., COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g., NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.

*Beyond Air’s LungFit PH is approved for commercial use in the United States, European Union, Australia, Thailand and New Zealand. Beyond Air’s other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.

About Nitric Oxide

Nitric Oxide (NO) is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post-cardiac surgery, and persistent pulmonary hypertension of the newborn to treat hypoxemia.

Additionally, NO is believed to play a key role in the innate immune system, and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria—including both gram-positive and gram-negative—but also against other diverse pathogens, including mycobacteria, viruses, fungi, yeast, and parasites, and has the potential to eliminate multi-drug-resistant strains.

Forward Looking Statements

This press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings, business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,” “expects,” “plans,” “anticipates,” “believes” “expects,” “intends,” “looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should” and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators; and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising, these forward-looking statements, except as required by applicable law.

Contacts

Investor Relations contacts


Corey Davis, Ph.D.


LifeSci Advisors, LLC


Cdavis@lifesciadvisors.com


(212) 915-2577

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.